New drug trial for Bullous Pemphigoid

Nottingham, England

- A five-year 'BLISTER' study is being coordinated by two universities, as they are seeking 250 bullous pemphigoid sufferers in the UK and Germany to participate in a randomized trial, according to Media-Newswire.

Half of participants will be treated with the current standard steroid drug, prednisolone, and the other half with doxycycline. Each participant will be followed for one year to see if doxycycline is more effective than prednisolone, but with fewer side effects.